We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 28, 2020

18FET-PET Predicts Survival Benefit From Bevacizumab Plus Radiotherapy in Patients With IDH Wild-Type Glioblastoma

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
MRI and 18FET-PET Predict Survival Benefit From Bevacizumab Plus Radiotherapy in Patients With IDH Wild-Type Glioblastoma: Results From the Randomized ARTE Trial
Clin. Cancer Res 2020 Sep 23;[EPub Ahead of Print], HG Wirsching, U Roelcke, J Weller, T Hundsberger, AF Hottinger, R von Moos, F Caparrotti, K Conen, L Remonda, P Roth, AF Ochsenbein, G Tabatabai, M Weller

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading